• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

雌激素和孕激素受体的免疫组织化学染色:评估阳性及确定切点的相关方面

Immunohistochemical staining of estrogen and progesterone receptors: aspects for evaluating positivity and defining the cutpoints.

作者信息

Jalava Päivi, Kuopio Teijo, Huovinen Riikka, Laine Juhana, Collan Yrjö

机构信息

Department of Pathology, University of Turku, Turku, Finland.

出版信息

Anticancer Res. 2005 May-Jun;25(3c):2535-42.

PMID:16080489
Abstract

BACKGROUND

Estrogen (ER) and progesterone (PgR) receptors are predictive and prognostic factors in breast cancer. The most suitable immunohistochemical cutpoints for dividing the tumors in hormone receptor-negatives and -positives may, however, need more consideration. We examined the association between breast cancer survival and cutpoints assessed by four different models. We looked for evidence for which patient subgroups could be handled best through applying different cutpoints.

MATERIALS AND METHODS

Three hundred and twenty-four samples of invasive breast cancer were immunohistochemically stained for ER and PgR, bcl-2 and erbB2. Fractions of ER- and PgR-positive cells and also ER and PgR staining scores were assessed. The fractions of stained cells and staining scores, respectively, were determined on the whole section area, and the area of most intense staining. Candidate cutpoints, dividing the patients into good and poor prognosis groups, were tested among all patients group, N+ and N- groups, premenopausal and postmenopausal patient groups. The correlation between immunohistochemistry results of ER, PgR, bcl-2 and erbB2 as well as SMI (standardized mitotic index), patient age, tumor size and axillary lymph node status were tested.

RESULTS

The ER score was correlated with age, SMI and bcl-2 positivity. The PgR score was correlated with erbB2 and bcl-2. Lobular carcinomas had higher staining scores of ER and PgR than ductal carcinomas.

CONCLUSION

In this material, ER was correlated with factors reflecting the differentiation of the tumor. On the basis of the ER and PgR immunohistochemistry cutpoint analysis, we found that the optimal cutpoints in different patient groups may not be the same.

摘要

背景

雌激素(ER)和孕激素(PgR)受体是乳腺癌的预测和预后因素。然而,对于将肿瘤分为激素受体阴性和阳性的最合适免疫组化切点可能需要更多考虑。我们研究了乳腺癌生存率与四种不同模型评估的切点之间的关联。我们寻找证据,以确定哪些患者亚组通过应用不同切点可以得到最佳处理。

材料与方法

对324例浸润性乳腺癌样本进行ER、PgR、bcl-2和erbB2免疫组化染色。评估ER和PgR阳性细胞分数以及ER和PgR染色评分。分别在整个切片区域和染色最强烈区域测定染色细胞分数和染色评分。在所有患者组、N+和N-组、绝经前和绝经后患者组中测试将患者分为预后良好和不良组的候选切点。测试ER、PgR、bcl-2和erbB2免疫组化结果以及标准化有丝分裂指数(SMI)、患者年龄、肿瘤大小和腋窝淋巴结状态之间的相关性。

结果

ER评分与年龄、SMI和bcl-2阳性相关。PgR评分与erbB2和bcl-2相关。小叶癌的ER和PgR染色评分高于导管癌。

结论

在本研究材料中,ER与反映肿瘤分化的因素相关。基于ER和PgR免疫组化切点分析,我们发现不同患者组的最佳切点可能不同。

相似文献

1
Immunohistochemical staining of estrogen and progesterone receptors: aspects for evaluating positivity and defining the cutpoints.雌激素和孕激素受体的免疫组织化学染色:评估阳性及确定切点的相关方面
Anticancer Res. 2005 May-Jun;25(3c):2535-42.
2
Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.乳腺导管癌中雌激素受体、孕激素受体及c-erbB2癌基因蛋白表达的改变
Cell Biol Int. 2008 Jun;32(6):698-707. doi: 10.1016/j.cellbi.2008.01.007. Epub 2008 Jan 25.
3
Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.高危早期乳腺癌中雌激素受体、孕激素受体和微管相关蛋白Tau的基因表达:在希腊合作肿瘤学组试验背景下寻找治疗获益的分子预测指标
Breast Cancer Res Treat. 2009 Jul;116(1):131-43. doi: 10.1007/s10549-008-0144-9. Epub 2008 Jul 31.
4
Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.重新评估辅助性乳腺癌试验:通过免疫组化法与提取法评估激素受体状态。
J Natl Cancer Inst. 2006 Nov 1;98(21):1571-81. doi: 10.1093/jnci/djj415.
5
Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.原发性非转移性乳腺癌及其相应的同步腋窝淋巴结转移的遗传与生物学特征之间的相关性
Breast Cancer Res Treat. 2007 Mar;101(3):279-84. doi: 10.1007/s10549-006-9300-2. Epub 2006 Jul 12.
6
Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.在一项比较来曲唑和他莫昔芬辅助治疗绝经后早期乳腺癌的随机试验(BIG 1-98)中,中心评估的雌激素和孕激素受体表达的预后及预测价值
J Clin Oncol. 2007 Sep 1;25(25):3846-52. doi: 10.1200/JCO.2007.11.9453. Epub 2007 Aug 6.
7
Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.具有单一激素受体阳性表型的乳腺癌的生物学和临床特征
J Clin Oncol. 2007 Oct 20;25(30):4772-8. doi: 10.1200/JCO.2007.12.2747. Epub 2007 Sep 17.
8
Immunofluorometric study of Bcl-2 and Bax expression in clinical fresh tumor samples from breast cancer patients.乳腺癌患者临床新鲜肿瘤样本中Bcl-2和Bax表达的免疫荧光测定研究
Anticancer Res. 2003 Jan-Feb;23(1B):565-8.
9
Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2.浸润性导管乳腺癌中基底型细胞角蛋白的免疫组化鉴定——与分级、分期、雌激素受体及人表皮生长因子受体2的关系
Pol J Pathol. 2005;56(3):107-10.
10
Predictive biological markers for response of invasive breast cancer to anthracycline/cyclophosphamide-based primary (radio-)chemotherapy.浸润性乳腺癌对基于蒽环类/环磷酰胺的原发性(放)化疗反应的预测性生物标志物。
Anticancer Res. 2005 Nov-Dec;25(6C):4615-21.

引用本文的文献

1
Relationship Study of The Verified H uman Epidermal Growth Factor Receptor 2 Amplification with Other Tumor Markers and Clinicohistopathological Characteristics in Patients with Invasive Breast Cancer, Using Chromogenic In Situ Hybridization.采用显色原位杂交技术对浸润性乳腺癌患者中经证实的人表皮生长因子受体2扩增与其他肿瘤标志物及临床组织病理学特征的关系研究
Cell J. 2019 Oct;21(3):322-330. doi: 10.22074/cellj.2019.6219. Epub 2019 Jun 15.
2
Discordance between original and central laboratories in ER and HER2 results in a diverse, population-based sample.在一个多样化的、基于人群的样本中,急诊室(ER)和人表皮生长因子受体2(HER2)检测结果的原始实验室与中心实验室之间存在不一致。
Breast Cancer Res Treat. 2017 Jan;161(2):375-384. doi: 10.1007/s10549-016-4061-z. Epub 2016 Nov 29.
3
CD105 expression on CD34-negative spindle-shaped stromal cells of primary tumor is an unfavorable prognostic marker in early breast cancer patients.原发性肿瘤中CD34阴性梭形基质细胞上CD105的表达是早期乳腺癌患者预后不良的标志物。
PLoS One. 2015 Mar 24;10(3):e0121421. doi: 10.1371/journal.pone.0121421. eCollection 2015.
4
Proliferative activity in Libyan breast cancer with comparison to European and Central African patients.利比亚乳腺癌患者的增殖活性与欧洲和中非患者的比较。
Biomed Res Int. 2013;2013:831714. doi: 10.1155/2013/831714. Epub 2013 Sep 11.
5
Clinical relevance of the reappraisal of negative hormone receptor expression in breast cancer.乳腺癌中阴性激素受体表达重新评估的临床相关性
Springerplus. 2013 Aug 9;2:375. doi: 10.1186/2193-1801-2-375. eCollection 2013.
6
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.美国临床肿瘤学会/美国病理学家学院乳腺癌雌激素和孕激素受体免疫组织化学检测指南建议。
Arch Pathol Lab Med. 2010 Jun;134(6):907-22. doi: 10.5858/134.6.907.
7
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.美国临床肿瘤学会/美国病理学家学会关于乳腺癌雌激素和孕激素受体免疫组织化学检测的指南建议。
J Clin Oncol. 2010 Jun 1;28(16):2784-95. doi: 10.1200/JCO.2009.25.6529. Epub 2010 Apr 19.
8
Pathobiological features of breast tumours in the State of Kuwait: a comprehensive analysis.科威特国乳腺肿瘤的病理生物学特征:一项综合分析。
J Carcinog. 2007 Sep 24;6:12. doi: 10.1186/1477-3163-6-12.
9
Lymph node status as a guide to selection of available prognostic markers in breast cancer: the clinical practice of the future?淋巴结状态作为乳腺癌可用预后标志物选择的指南:未来的临床实践?
Diagn Pathol. 2006 Nov 8;1:41. doi: 10.1186/1746-1596-1-41.